Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Samuraciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Carrick Doses First Patient In CT7439 Phase 1 Trial
    Carrick Doses First Patient In CT7439 Phase 1 Trial

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    Carrick Announces First Patient Dosed in Phase 1b/2 Trial of Samuraciclib
    Carrick Announces First Patient Dosed in Phase 1b/2 Trial of Samuraciclib

    14 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/14/2829038/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1b-2-Clinical-Trial-of-Samuraciclib-in-Combination-with-Vepdegestrant-in-Patients-with-Advanced-Breast-Cancer.html

    GLOBENEWSWIRE
    14 Feb 2024
    Share Share
    Carrick Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib
    Carrick Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib

    15 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/15/2797014/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2b-Clinical-Trial-of-Samuraciclib-in-Combination-with-Fulvestrant-in-Patients-with-Advanced-HR-HER2-Breast-Cancer.html

    GLOBENEWSWIRE
    15 Dec 2023
    Share Share
    Carrick Announces First Patient Dosed in Phase 2 Trial of Samuraciclib
    Carrick Announces First Patient Dosed in Phase 2 Trial of Samuraciclib

    18 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/18/2762408/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Samuraciclib-in-Combination-with-Elacestrant-in-Patients-with-Advanced-Breast-Cancer.html

    GLOBENEWSWIRE
    18 Oct 2023
    Share Share
    Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy
    Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy

    20 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/carrick-therapeutics-menarini-breast-cancer/

    CLINICALTRIALSARENA
    20 Dec 2022
    Share Share
    Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy
    Carrick Therapeutics and Menarini to evaluate breast cancer combo therapy

    20 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/carrick-therapeutics-menarini-breast-cancer/

    CLINICALTRIALSARENA
    20 Dec 2022
    Share Share